Migraine Drugs Market is estimated to be US$ 8.3 billion by 2030 with a CAGR of 15.70% during the forecast period

 


Migraine therapies are designed to alleviate symptoms or prevent future episodes in migraine sufferers. The rising frequency of migraines problems around the world, as well as increased awareness of novel drug classes, are driving the expansion of the migraine market. The introduction of calcitonin gene-related peptide (CGRP) is also predicted to boost the industry's growth. Migraine headaches are characterised by a strong and recurrent headache, as well as phonophobia, photophobia, and nausea. The disorder is caused by hereditary factors. Migraine episodes can be triggered by emotional imbalances such as despair, stress, worry, shock, and enthusiasm. There have been a variety of drug options for preventing and treating migraines, but they all have serious side effects, such as weight gain, dizziness, nausea, and more in an adult with no underlying medical conditions. Sumatriptan is the safest therapeutic option for pregnant women, and anticonvulsant medications are not recommended. However, the approval of a new class of medicine specifically developed to treat migraines by the US Food and Drug Administration has had a favourable impact on the market. Aimovig (Erenumab), Emgality, and Ajovy are the three new FDA-approved medications. Emgality (galcanezumab-gnlm), a 120 mg injectable for the preventative treatment of migraine in adults, was approved by the US Food and Drug Administration (FDA) in September 2018.

 Region Analysis:

Geographically, North America dominates the market. According to the American Migraine Association, migraine affects over 36 million Americans, or around 12% of the people in the region. The market is expected to rise due to increased vendor focus on growing markets such as Asia-Pacific, Latin America, and the Middle East and Africa. Moreover, due to rising demand for better healthcare services and strengthened healthcare infrastructure, Asia-Pacific is expected to see significant growth in the future. Due to increased demand for better healthcare facilities and advances in healthcare infrastructure, Asia-Pacific is expected to grow significantly in the future. Furthermore, because the developed markets are somewhat saturated, this region presents exceptional potential for venture capitalists and investors.

 Key Development:

·On 2022, The European Medicines Agency (EMA) has given rimegepant, a calcitonin gene-related

peptide (CGRP) receptor antagonist, a positive opinion, recommending the 75 mg dose of rimegepant

(available as an orally dissolving tablet) for marketing authorization for both the acute treatment of

migraine with or without a headache.

·In 2022, ELYXYBTM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral

solution for the acute treatment of migraine with or without aura in adults, was launched and made

available in the United States today by BioDelivery Sciences International, Inc., a growing specialty

pharmaceutical company dedicated to patients living with serious and complex chronic conditions.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/833

 Segmentation:

The Global Migraine Drugs Market accounted for US$ 2.2 billion in 2020 and is estimated to be US$ 8.3 billion by 2030 and is anticipated to register a CAGR of 15.70%. The market report has been segmented on the basis of treatment, route of administration, distribution channel, and region.

·By treatment, the global migraine drugs market is segmented into abortive or acute and prophylactic

or preventive. Abortive or acute sub-segment is categorized into triptans, ergot alkaloids, and anti

nausea medications. Further, prophylactic or preventive sub-segment is bifurcated into botulinum

toxin, topiramate, and glucocorticoids.

·By route of administration, the global migraine drugs market is classified into oral, injectable, and

others. Others route of administration sub-segment is nasal spray and transdermal patch.

·By distribution channel, the global migraine drugs market is categorized into retail pharmacies,

hospital pharmacies, and online pharmacies.

·By region, North America migraine drugs market is expected to account for major revenue share in

global migraine drugs market, followed by other regions. This is attributed to rising penetration of

migraine in the countries of the North America region. The Asia Pacific migraine drugs market is

emerging market in the global migraine drugs market in 2018.

Competitive Analysis:                                                                                                 

The prominent player operating in the global migraine drugs market includes Pfizer Inc, GlaxoSmithKline plc, Allergan plc, Amgen Inc, Eli Lilly and Company, Teva Pharmaceuticals USA, Inc, Biohaven Pharmaceutical Holding Company Ltd, Johnson & Johnson, Novartis Pharmaceuticals Canada Inc., and Alembic Pharmaceuticals Limited.

 About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

Prophecy Market Insights

  1 860 531 2701

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com

 

 

Comments

Post a Comment

Popular posts from this blog

Food Allergy Market is estimated to be US$ 7.0 Bn by 2030 with a CAGR of 7.9% during the forecast period

Image
  The Food Allergy Market accounted for US$ 3.3 Bn in 2020 and is estimated to be US$ 7.0 Bn by 2030 and is anticipated to register a CAGR of 7.9%. Food allergy market is driven by various factors such as globalization of food trade, growth in incidences of allergic disorders among consumers. Food allergy is an abnormal response cause by various different food products such as milk, soy, wheat, peanuts and various products which are present in the market. Food allergy hampers the immune response of the body, as sometimes body is not able to fight with certain microbes which enter our body through various food products and therefore leading to food allergic responses.   The report " Food Allergy Market, By Technology (Biosensor-Based, Immunoassay-Based, ELISA PCR Based and Other Technologies), By  Source (Milk, Egg,  Soy, Tree Nuts, Peanuts, Wheat, Seafood and Others), By Diagnosis (Primary and Secondary), By Treatment (Anti Histamines and Adrenaline), By End – Us...
Read more

Infusion Pumps Market is estimated to be US$ 24.63 billion by 2030 with a CAGR of 9.90% during the forecast period

Image
  The Infusion Pumps Market accounted for US$ 12.34 billion in 2020 and is estimated to be US$ 24.63 billion by 2030 and is anticipated to register a CAGR of 9.90%..  An infusion pump infuses fluids, medication or nutrients into a patient's cardiovascular system. It’s generally used intravenously, although subcutaneous, arterial and epidural infusions are occasionally used. Infusion pumps can administer fluids in ways in which would be impractically expensive or unreliable if performed manually by nursing staff. for instance , they will administer as little as 0.1 mL per hour injections (too small for a drip), injections every minute, injections with repeated boluses requested by the patient, up to maximum number per hour (e.g. in patient-controlled analgesia), or fluids whose volumes vary by the time of day.  Because they will also produce quite high but controlled pressures, they will inject controlled amounts of fluids subcutaneously (beneath the skin), or epidurally ...
Read more

Poultry Vaccines Market is estimated to be US$ 3.47 billion by 2030 with a CAGR of 5.8% during the forecast period

Image
  The Poultry Vaccines Market accounted for US$ 1.98 billion in 2020 and is estimated to be US$ 3.47 billion by 2030 and is anticipated to register a CAGR of 5.8%. Vaccination is an important aspect of the chicken flock's health management. Vaccinating birds against a variety of diseases prevents the spread of disease. A vaccine helps to avoid a disease by inducing or enhancing the production of antibodies in the bird's immune system, which then fight the invading causative organisms. Chicken vaccines play a crucial part in keeping poultry flocks healthy. Vaccinating the chicken flock helps to prevent a variety of diseases. Vaccines create antibodies that aid the body of the bird in fighting off invading pathogens. The report " Poultry Vaccines Market, By Type (Live Vaccines and Killed Vaccines), By Application (Chicken and Duck & Goose), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast ...
Read more